- Stocks
- Healthcare
- NASDAQ: AMGN

Price (delayed)

$223.39

Market cap

$130.84B

P/E Ratio

18.12

Dividend/share

$6.25

EPS

$12.33

Enterprise value

$155.92B

Amgen's equity has increased by 12% from the previous quarter

The revenue has grown by 3.1% year-on-year

AMGN's quick ratio is up by 45% since the previous quarter but it is down by 34% year-on-year

The P/E is 25% below the 5-year quarterly average of 24.3 but 6% above the last 4 quarters average of 17.1

The debt rose by 12% year-on-year and by 7% since the previous quarter

The net income has contracted by 8% YoY and by 4.9% from the previous quarter

What are the main financial stats of AMGN

Market
Valuations
Earnings

Shares outstanding

585.69M

Market cap

$130.84B

Enterprise value

$155.92B

Price to earnings (P/E)

18.12

Price to book (P/B)

12.33

Price to sales (P/S)

5.41

EV/EBIT

16.3

EV/EBITDA

12.37

EV/Sales

6.42

Revenue

$24.3B

EBIT

$9.57B

EBITDA

$12.6B

Free cash flow

$10.21B

Per share
Balance sheet
Liquidity

EPS

$12.33

Free cash flow per share

$17.36

Book value per share

$18.12

Revenue per share

$41.33

TBVPS

$55.08

Total assets

$65.01B

Total liabilities

$54.35B

Debt

$34.22B

Equity

$10.66B

Working capital

$12.37B

Debt to equity

3.21

Current ratio

2.18

Quick ratio

1.6

Net debt/EBITDA

1.99

Margins
Efficiency
Dividend

EBITDA margin

51.9%

Gross margin

78.2%

Net margin

30%

Operating margin

37.9%

Return on assets

11.9%

Return on equity

71.7%

Return on invested capital

22.5%

Return on capital employed

17.6%

Return on sales

39.4%

Dividend yield

2.8%

DPS

$6.25

Payout ratio

50.7%

How has the Amgen stock price performed over time

How have Amgen's revenue and profit performed over time

Revenue

$24.3B

Gross profit

$19.01B

Operating income

$9.2B

Net income

$7.3B

Gross margin

78.2%

Net margin

30%

The net margin has declined by 11% year-on-year and by 6% since the previous quarter

The company's operating margin fell by 9% YoY and by 5% QoQ

The net income has contracted by 8% YoY and by 4.9% from the previous quarter

AMGN's operating income is down by 7% year-on-year and by 3.7% since the previous quarter

What is Amgen's growth rate over time

What is Amgen stock price valuation

P/E

18.12

P/B

12.33

P/S

5.41

EV/EBIT

16.3

EV/EBITDA

12.37

EV/Sales

6.42

The P/E is 25% below the 5-year quarterly average of 24.3 but 6% above the last 4 quarters average of 17.1

AMGN's EPS is down by 4% since the previous quarter and by 2.9% year-on-year

The stock's price to book (P/B) is 62% more than its 5-year quarterly average of 7.6 but 3.7% less than its last 4 quarters average of 12.8

Amgen's equity has increased by 12% from the previous quarter

The revenue has grown by 3.1% year-on-year

The P/S is 2.1% more than the 5-year quarterly average of 5.3

How efficient is Amgen business performance

The ROIC has grown by 18% YoY but it has contracted by 2.6% from the previous quarter

AMGN's return on sales is down by 12% year-on-year and by 7% since the previous quarter

The ROE has grown by 9% YoY but it has contracted by 4.5% from the previous quarter

AMGN's return on assets is down by 7% since the previous quarter and by 4% year-on-year

What is AMGN's dividend history

DPS

$6.25

Dividend yield

2.8%

Payout ratio

50.7%

Recent dividends

How did Amgen financials performed over time

Amgen's total assets is 20% more than its total liabilities

AMGN's quick ratio is up by 45% since the previous quarter but it is down by 34% year-on-year

Amgen's current ratio has increased by 37% from the previous quarter but it has decreased by 25% YoY

AMGN's debt to equity is up by 13% YoY but it is down by 4.5% QoQ

The debt rose by 12% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.